# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: K063356

# B. Purpose for Submission:

To seek clearance for modifications to:

• Stratus® CS Acute Care™ D-dimer (DDMR) TestPak (Assay) • Stratus® CS Acute Care™ D-dimer (DDMR) CalPak (Calibrator) • Stratus® CS Acute Care™ D-dimer (DDMR) DilPak (Diluent)

# C. Measurand:

D-Dimer

D. Type of Test: Solid phase Radial Partition Immunoassay (RPIA)

# E. Applicant:

Dade Behring Inc.

# F. Proprietary and Established Names:

• Stratus® CS Acute Care™ D-dimer (DDMR) TestPak • Stratus® CS Acute Care™ D-dimer (DDMR) CalPak Stratus® CS Acute Care™ D-dimer (DDMR) DilPak

# G. Regulatory Information:

1. Regulation section:   
21 CFR 864.7320

2. Classification: Class II

3. Product code:

DAP

4. Panel: Hematology

# H. Intended Use:

1. Intended use(s):

# Method:

The Stratus $\textsuperscript { \textregistered }$ CS Acute Care™ D-dimer (DDMR) assay is an in vitro diagnostic test for the quantitative measurement of cross-linked fibrin degradation products (Ddimer) in human citrated or heparinized plasma.

# Calibrator:

The Stratus $\textsuperscript { \textregistered }$ CS Acute Care™ D-dimer (DDMR) Calibrator is an in vitro diagnostic product intended to be used for calibration of the Stratus $\textsuperscript { \textregistered }$ CS Acute Care™ D-dimer (DDMR) method.

# Diluent:

The Stratus $\textsuperscript { \textregistered }$ CS Acute Care™ D-dimer (DDMR) Diluent is an in vitro diagnostic product intended to be used in conjunction with the Acute Care™ D-dimer TestPak, for the measurement of samples with elevated levels of D-Dimer.

2. Indication(s) for use:

# Method:

The Stratus $\textsuperscript { \textregistered }$ CS Acute Care™ D-dimer (DDMR) assay is intended for use as an aid in the diagnosis of venous thromboembolism (VTE) [deep vein thrombosis (DVT) or pulmonary embolism (PE)]. This method is for use by trained healthcare professionals in the clinical laboratory and point of care (POC) settings.

# Calibrator:

The Stratus $\textsuperscript { \textregistered }$ CS Acute Care™ D-dimer (DDMR) Calibrator is an in vitro diagnostic product intended to be used for calibration of the Stratus $\textsuperscript { \textregistered }$ CS Acute Care™ D-dimer (DDMR) method.

# Diluent:

The Stratus $\textsuperscript { \textregistered }$ CS Acute Care™ D-dimer (DDMR) Diluent is an in vitro diagnostic product intended to be used in conjunction with the Acute Care™ D-dimer assay for the measurement of samples with elevated levels of D-Dimer.

3. Special conditions for use statement(s):

4. Special instrument requirements:

Stratus® CS STAT Fluorometric Analyzer

# I. Device Description:

The Stratus® CS Acute Care™ D-Dimer (DDMR) TestPak is an in vitro diagnostic test for the quantitative determination of D-Dimer in human plasma. The principle of assay is based on solid phase Radial Partition Immunoassay (RPIA) technology. Elevated concentrations of D-Dimer are indicative of the presence of a clot and have been reported in DVT, PE, DIC, during pregnancy, use of contraceptives, increased age, and trauma.

The D-dimer TestPak is used in conjunction with Stratus® CS Acute Care™ D-dimer (DDMR) CalPak and Stratus® CS Acute Care™ D-dimer (DDMR) DilPak to perform the D-dimer assay, calibration, and quality control on the Stratus® CS STAT Fluorometric Analyzer.

The Stratus® CS Acute Care™ D-dimer method uses whole blood collected in lithium heparin or sodium citrate. Samples are automatically processed by the analyzer via centrifugation. The plasma obtained after centrifugation is used in the analysis. Heparinized or citrated plasma dispensed in a sample cups can also be used by this method. The instrument automatically calculates and prints the concentration of D-dimer in $\mathtt { n g / m L } [ \mu \mathbf { g } / \mathrm { L } ]$ FEU. The D-dimer assay range is $6 { - } 5 0 0 0 ~ \mathrm { n g / m l [ \mu g / L ] }$ FEU, samples between 5000 and $1 7 , 5 0 0 \mathrm { n g / m L \left[ \mu g / L \right] }$ FEU may be run using a D-dimer DilPak along with a D-dimer TestPak. The instrument will automatically perform a dilution of the sample.

Samples with D-dimer concentration in excess of $1 7 , 5 0 0 \mathrm { n g / m L \left[ \mu g / L \right] }$ FEU can be tested after manually diluting the sample with normal saline. Manual dilution is not recommended for healthcare professionals in the Point of Care (POC) setting and the results should be reported as $> 1 7 , 5 0 0 \ \mathrm { n g / m l [ \mu g / L ] }$ FEU.

# J. Substantial Equivalence Information:

1. Predicate device name(s):

• Stratus® CS D-dimer TestPak • Stratus® CS D-dimer DilPak • Stratus® CS D-dimer CalPak

2. Predicate 510(k) number(s):

• K051597   
• K022976   
• K022977

3. Comparison with predicate:

A. Method: Stratus® CS Acute Care™ D-dimer TestPak Predicate: Stratus® CS D-dimer TestPak, K022976/K051597

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Principle</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Solid Phase Radial PartitionImmunoassay, quantitativemeasurement of D-Dimer.</td></tr><tr><td rowspan=1 colspan=1>Formulation</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Dendrimer monoclonalantibody</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Citrated or HeparinizedPlasma</td></tr><tr><td rowspan=1 colspan=1>Instrumentation</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Stratus® CS STATFluorometric Analyzer</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>6-5000 ng/mL [μg/L] FEU</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>450 ng/mL [μg/L] FEU</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>New Name</td><td rowspan=1 colspan=1>StratusRCS AcuteCareTM D-dimer TestPak</td><td rowspan=1 colspan=1>StratusCS D-dimer TestPak</td></tr><tr><td rowspan=1 colspan=1>Indications for Use</td><td rowspan=1 colspan=1>Add: This method is foruse by trained health careprofessionals in theclinical laboratory andpoint of care (POC)settings</td><td rowspan=1 colspan=1>Quantitative measurement ofcrossed-linked fibrindegradation product incitrated or heparinized plasmaand as an aid in the diagnosisof VTE</td></tr><tr><td rowspan=1 colspan=1>Summary</td><td rowspan=1 colspan=1>Add: increased D-dimerlevels have also beenreported in many clinicalconditions (e.g., duringpregnancy, use ofcontraceptives, increasedage and trauma)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Test Result</td><td rowspan=1 colspan=1>- Automated dilution &amp;manual dilution resultsfor health careprofessional in theclinical laboratory- Automated dilution forPOC only</td><td rowspan=1 colspan=1>Automated &amp; manual dilutionresults for health careprofessional in the clinicallaboratory.</td></tr></table>

# B. Calibrator: Stratus® CS Acute Care™ D-dimer CalPak

Predicate: Stratus® CS D-dimer CalPak, K022977

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>For calibration of the D-dimermethod</td></tr><tr><td rowspan=1 colspan=1>Formulation</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Calibrator level at anapproximate concentration of3500 ng/mL [μg/L] FEU ineach of three well</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>New Name</td><td rowspan=1 colspan=1>StratusCS AcuteCareTM D-dimer CalPak</td><td rowspan=1 colspan=1>StratusCS D-dimer CalPak</td></tr></table>

C. Diluent: Stratus® CS Acute Care™ D-Dimer DilPak

Predicate: Stratus® CS D-dimer DilPak, K022976

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>To be used in conjunctionwith the D-dimer TestPak</td></tr><tr><td rowspan=1 colspan=1>Formulation</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Liquid buffered bovineprotein matrix</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>New name</td><td rowspan=1 colspan=1>StratusCS AcuteCareTM D-dimer DilPak</td><td rowspan=1 colspan=1>Stratus®CS D-dimer DilPak</td></tr></table>

# K. Standard/Guidance Document referenced (if applicable):

NCCLS guideline EP15-A: User Demonstration of Performance for Precision and Accuracy: Approved Guidelines

# L. Test Principle:

Method: It is a two-site sandwich assay based upon solid phase Radial Partition Immunoassay (RPIA) technology. Dendrimer linked monoclonal antibody is then added to the center portion of a square piece of glass fiber paper in the TestPak. This antibody recognizes a distinct antigenic site on the D-Dimer molecule. Sample is then added onto the paper where it reacts with the immobilized antibody. A conjugate, consisting of enzyme-labeled monoclonal antibody directed against a second distinct antigenic site on the D-dimer molecule, is added onto the reaction zone of the paper. The enzyme-labeled antibody reacts with the bound D-Dimer, forming an antibody-antigen-labeled antibody sandwich. Then the unbound labeled antibody is eluted from the reaction zone. The initiation of the enzyme activity occurs simultaneously with the wash since substrate for the enzyme was included in the wash solution. The enzymatic rate of the bound fraction increases directly with the concentration of the D-Dimer in the sample. The reaction rate is then be measured by an optical system that monitors the reaction rate via front surface fluorescence. The microprocessor within the analyzer performs all data analysis.

Calibrator: The D-dimer CalPak contains D-dimer in a liquid buffered bovine protein matrix which contains one calibrator level at an approximate concentration of 3500 $\mathrm { { n g / m L } }$ in each of three wells. The kit consists of five CalPaks at a single calibrator level and is used for calibration of the Stratus® CS Acute Care™ method.

Diluent: The D-dimer DilPak contains a liquid buffered bovine protein matrix which is used in conjunction with the D-dimer TestPak for the measurement of samples with elevated levels of D-Dimer.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision analysis was performed to support the addition of Point of Care (POC) to the indication for use. The testing was completed at three different locations: Clinical Laboratory (LAB), Emergency Department (ED), and Cardiac Care Unit (CCU) at three external sites.

Two levels of plasma pools were performed in replicates of four over a period of five days $( \mathrm { N } { = } 2 0 )$ ) by LAB, ED, and CCU personnel on the Status instruments located in their respective areas. ED and CCU personnel had no formal laboratory training. Within-Run (WR) and total coefficients of variation $( \% C V )$ were calculated according to the NCCLS EP-15A.

Results are summarized below:

# Point of Care Site 1

Point of Care Site 2   

<table><tr><td rowspan=1 colspan=1>Locations / Level</td><td rowspan=1 colspan=1>Mean(ng/mL) [μg/L]FEU</td><td rowspan=1 colspan=1>WR SD (%CV)</td><td rowspan=1 colspan=1>Total SD (%CV)</td></tr><tr><td rowspan=1 colspan=1>Lab  Plasma Pool L1</td><td rowspan=1 colspan=1>481.6</td><td rowspan=1 colspan=1>12.48(2.6)</td><td rowspan=1 colspan=1>16.12(3.3)</td></tr><tr><td rowspan=1 colspan=1>ED - Plasma Pool L1</td><td rowspan=1 colspan=1>526.4</td><td rowspan=1 colspan=1>22.06(4.2)</td><td rowspan=1 colspan=1>22.85(4.3)</td></tr><tr><td rowspan=1 colspan=1>CCU  Plasma Pool L1</td><td rowspan=1 colspan=1>512.9</td><td rowspan=1 colspan=1>36.96(7.2)</td><td rowspan=1 colspan=1>36.96(7.2)</td></tr><tr><td rowspan=1 colspan=1>Lab  Plasma Pool L2</td><td rowspan=1 colspan=1>2375.8</td><td rowspan=1 colspan=1>122.79(5.2)</td><td rowspan=1 colspan=1>228.13(9.6)</td></tr><tr><td rowspan=1 colspan=1>ED - Plasma Pool L2</td><td rowspan=1 colspan=1>2539.9</td><td rowspan=1 colspan=1>96.45(3.8)</td><td rowspan=1 colspan=1>114.29(4.5)</td></tr><tr><td rowspan=1 colspan=1>CCU  Plasma Pool L2</td><td rowspan=1 colspan=1>2541.0</td><td rowspan=1 colspan=1>187.67(7.4)</td><td rowspan=1 colspan=1>187.67(7.4)</td></tr></table>

Point of Care Site 3   

<table><tr><td rowspan=1 colspan=1>Locations / Level</td><td rowspan=1 colspan=1>Mean(ng/mL) [μg/L]FEU</td><td rowspan=1 colspan=1>WR SD (%CV)</td><td rowspan=1 colspan=1>Total SD (%CV)</td></tr><tr><td rowspan=1 colspan=1>Lab - Plasma Pool L1</td><td rowspan=1 colspan=1>502.7</td><td rowspan=1 colspan=1>15.86(3.2)</td><td rowspan=1 colspan=1>32.11(6.4)</td></tr><tr><td rowspan=1 colspan=1>ED - Plasma Pool L1</td><td rowspan=1 colspan=1>468.0</td><td rowspan=1 colspan=1>19.29(4.1)</td><td rowspan=1 colspan=1>23.55(5.0)</td></tr><tr><td rowspan=1 colspan=1>CCU  Plasma Pool L1</td><td rowspan=1 colspan=1>482.6</td><td rowspan=1 colspan=1>8.40(1.7)</td><td rowspan=1 colspan=1>10.70(2.2)</td></tr><tr><td rowspan=1 colspan=1>Lab  Plasma Pool L2</td><td rowspan=1 colspan=1>2433.5</td><td rowspan=1 colspan=1>78.51(3.2)</td><td rowspan=1 colspan=1>120.14(4.9)</td></tr><tr><td rowspan=1 colspan=1>ED - Plasma Pool L2</td><td rowspan=1 colspan=1>2350.0</td><td rowspan=1 colspan=1>105.89(4.5)</td><td rowspan=1 colspan=1>142.73(6.1)</td></tr><tr><td rowspan=1 colspan=1>CCU -Plasma Pool L2</td><td rowspan=1 colspan=1>2356.3</td><td rowspan=1 colspan=1>140.46(6.0)</td><td rowspan=1 colspan=1>140.46(6.0)</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Locations / Level</td><td rowspan=1 colspan=1>Mean(ng/mL) [μg/L]FEU</td><td rowspan=1 colspan=1>WR SD (%CV)</td><td rowspan=1 colspan=1>Total SD (%CV)</td></tr><tr><td rowspan=1 colspan=1>Lab - Plasma Pool L1</td><td rowspan=1 colspan=1>446.4</td><td rowspan=1 colspan=1>10.63(2.4)</td><td rowspan=1 colspan=1>15.94(3.6)</td></tr><tr><td rowspan=1 colspan=1>ED - Plasma Pool L1</td><td rowspan=1 colspan=1>484.4</td><td rowspan=1 colspan=1>14.80(3.1)</td><td rowspan=1 colspan=1>14.80(3.1)</td></tr><tr><td rowspan=1 colspan=1>CCU  Plasma Pool L1</td><td rowspan=1 colspan=1>458.4</td><td rowspan=1 colspan=1>16.90(3.7)</td><td rowspan=1 colspan=1>19.72(4.3)</td></tr><tr><td rowspan=1 colspan=1>Lab  Plasma Pool L2</td><td rowspan=1 colspan=1>2254.6</td><td rowspan=1 colspan=1>86.50(3.8)</td><td rowspan=1 colspan=1>108.48(4.8)</td></tr><tr><td rowspan=1 colspan=1>ED  Plasma Pool L2</td><td rowspan=1 colspan=1>2404.4</td><td rowspan=1 colspan=1>83.61(3.5)</td><td rowspan=1 colspan=1>94.84(3.9)</td></tr><tr><td rowspan=1 colspan=1>CCU - Plasma Pool L2</td><td rowspan=1 colspan=1>2316.7</td><td rowspan=1 colspan=1>107.43(4.6)</td><td rowspan=1 colspan=1>107.43(4.6)</td></tr></table>

b. Linearity/assay reportable range:

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

d. Detection limit:

e. Analytical specificity:

f. Assay cut-off:

2. Comparison studies:

a. Method comparison with predicate device: Method comparison studies were performed to compare the performance obtained with the Stratus® CS Acute Care™ D-dimer TestPak with non

laboratory personnel (ED, CCU) versus laboratory personnel (LAB) at 3 evaluation sites.

The results are summarized below:

<table><tr><td rowspan=1 colspan=1>POC Site 1</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept ng/mL [μg/L]FEU</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>Standard Error ofthe Regression</td><td rowspan=1 colspan=1>n</td></tr><tr><td rowspan=1 colspan=1>Lab v ED</td><td rowspan=1 colspan=1>1.12 ± 0.01</td><td rowspan=1 colspan=1>-8.4 ± 14.3</td><td rowspan=1 colspan=1>0.998</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>64</td></tr><tr><td rowspan=1 colspan=1>Lab v CCU</td><td rowspan=1 colspan=1>1.09 ± 0.02</td><td rowspan=1 colspan=1>-32.2 ± 25.6</td><td rowspan=1 colspan=1>0.992</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=1 colspan=1>POC Site 2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Lab v ED2</td><td rowspan=1 colspan=1>0.93 ± 0.01</td><td rowspan=1 colspan=1>-2.01 ± 16.2</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>67</td></tr><tr><td rowspan=1 colspan=1>Lab v CCU2</td><td rowspan=1 colspan=1>0.91 ± 0.02</td><td rowspan=1 colspan=1>-28.9 ± 25.2</td><td rowspan=1 colspan=1>0.991</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>65</td></tr><tr><td rowspan=1 colspan=1>POC Site 3</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Lab v ED3</td><td rowspan=1 colspan=1>0.99 ± 0.02</td><td rowspan=1 colspan=1>-4.62 ± 28.2</td><td rowspan=1 colspan=1>0.989</td><td rowspan=1 colspan=1>176</td><td rowspan=1 colspan=1>74</td></tr><tr><td rowspan=1 colspan=1>Lab v CCU3</td><td rowspan=1 colspan=1>1.00 ± 0.01</td><td rowspan=1 colspan=1>-3.75 ± 22.7</td><td rowspan=1 colspan=1>0.994</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>75</td></tr></table>

1 range of results $= 3 6 - 4 2 2 0 \mathrm { n g / m L }$ 2 range of results $= 1 3 3 - 3 9 7 4 \mathrm { n g / m L }$ 3 range of results $= 5 6 - 4 7 7 8 ~ \mathrm { n g / m L }$

b. Matrix comparison:

3. Clinical studies:

a. Clinical Sensitivity:   
b. Clinical specificity:   
c. Other clinical supportive data (when a. and b. are not applicable):

4. Clinical cut-off:

5. Expected values/Reference range:

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.